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httpABSTRACT
Background: Symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema in children
cluster at both the individual and population levels.
Objectives: To assess individual-level and school-level risk factors for symptoms of rhino-
conjunctivitis and compare them to corresponding associations with symptoms of asthma and
eczema in Phase Three of the International Study of Asthma and Allergies in Childhood.
Methods: We studied 116,863 children aged 6–7 years from 2163 schools in 59 centres and 22
countries and 224,436 adolescents aged 13–14 years from 2037 schools in 97 centres in 41
countries. Multilevel logistic regression models were fitted with random intercepts for school,
centre, and country, adjusting for sex and maternal education at the child level. Associations be-
tween symptoms and a range of lifestyle and environmental risk factors were assessed for both the
child's exposure and mean exposure at the school. Models were fitted for rhinoconjunctivitis,
asthma, and eczema singly (unimorbidity) and for combinations of these conditions
(multimorbidity).
Results: Generally, associations between symptoms and exposures at the school level were
similar in direction and magnitude to those at the child level. Associations with multimorbidity
were stronger than for unimorbidity, particularly in individuals with symptoms of all three diseases,
but risk factor associations found in conventional single disease analyses persisted among children
with only one condition, after excluding multimorbid groups.
Comparisons of individuals with only one disease showed that many risk factor associations were
consistent across the three conditions. More strongly associated with asthma were low birth-
weight, cat exposure in infancy, and current maternal smoking. Current paracetamol use was moreartment of Medical Statistics, London School of Hygiene and Tropical
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http://doi.org/10.1016/j.waojou.2020.100123strongly associated with asthma and rhinoconjunctivitis than eczema. Breastfeeding was more
strongly associated with eczema than asthma or rhinoconjunctivitis.
The direction and magnitude of most risk factor associations were similar in affluent and non-
affluent countries, although notable exceptions include farm animal contact in infancy and
larger sibships, which were associated with increased risk of rhinoconjunctivitis in non-affluent
countries but reduced risk in affluent countries. In both age groups, current paracetamol use
increased risk of each disease to a greater extent in affluent countries than in non-affluent coun-
tries. Effects of paracetamol and antibiotics in infancy were more consistent between richer and
poorer settings.
Conclusions: Most of the environmental and lifestyle correlates of rhinoconjunctivitis, asthma and
eczema in childhood display similarity across the three conditions, even in less affluent settings
where allergic sensitisation is less likely to explain the concordant epidemiological patterns.
Trial registration: Not applicable.
Keywords: Rhinoconjunctivitis, Asthma, Eczema, Multimorbidity, Globaldifferences in the epidemiological patterns of theINTRODUCTION
The International Study of Asthma and Allergies
in Childhood (ISAAC) has used standardised
questionnaires to assess prevalence, time trends,
and epidemiological associations for symptoms of
non-infective rhinoconjunctivitis, asthma, and
eczema among children from over 300 centres in
more than 100 countries worldwide.1,2 More
detailed biomedical assessment in 30 diverse
centres in ISAAC Phase Two3–5 has demonstrated
that allergic sensitisation accounts for a much
lower proportion of rhinoconjunctivitis, asthma,
and eczema symptoms in centres from low- and
middle-income countries than it does in more
affluent settings which feature more prominently in
the epidemiological literature.
Previous publications from ISAAC Phase Three
have presented the associations of each of the 3
diseases with single environmental or lifestyle fac-
tors.6–19 More recently, these have been
summarised across multiple risk factors for
symptoms of asthma20 and eczema,21 and
comparisons have been made between the
relationship of each of these diseases to
exposures measured at the level of individuals
and exposures averaged at the area level (schools).
In this paper, we apply the multi-level analytical
approach to symptoms of rhinoconjunctivitis and
extend our overview to assess similarities and3 diseases, singly and in combination. We also
compare these patterns between centres from
higher-income and lower-income countries.METHODS
Study design
A brief summary of the ISAAC Phase Three
methods are presented in this paper and more
details are available elsewhere.1 ISAAC Phase
Three was a multi-centre, multi-country, cross-
sectional study of children (age 6–7 years) and
adolescents (age 13–14 years). Within a defined
geographical area (centre), a sample of schools
were chosen at random. All children within the age
groups in those schools were asked to partici-
pate.1 The Phase Three survey took place in 2000–
2003 and included two standardised
questionnaires (http://isaac.auckland.ac.nz); the
original symptom questionnaire from ISAAC
Phase One1,2 with information on symptoms of
asthma, eczema and rhinoconjunctivitis, and an
environmental questionnaire which collected data
on a range of possible risk factors for the
development of these disorders.1
Variable definitions
The 3 main outcomes of interest, asthma,
eczema, and rhinoconjunctivitis, are defined using
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are likely to be undiagnosed in many cases as
people seek to self-treat (particularly rhino-
conjunctivitis), and the rate of doctor diagnoses is
likely to vary widely from country to country. Thus,
outcomes assessed in the ISAAC questionnaire are
based on a description of symptoms rather than a
diagnosis of disease.
Rhinoconjunctivitis is defined by positive re-
sponses to all of the following 3 questions:
Have you [has your child] ever had a problem
with sneezing, or a runny, or blocked nose
when you did not have a cold or the flu?
In the past 12 months, have you [has your
child] had a problem with sneezing, or a
runny, or blocked nose when you [he/she] did
not have a cold or the flu?
In the past 12 months, has this nose
problem been accompanied by itchy-watery
eyes?
Eczema is defined by positive responses to all of
the following 3 questions:
Have you [has your child] ever had an itchy
rash which was coming and going for at least
six months?
Have you [has your child] had this itchy
rash at any time in the past 12 months?
Has this itchy rash at any time affected any
of the following places: the folds of the el-
bows, behind the knees, in front of the ankles,
under the buttocks, or around the neck, ears
or eyes?
Asthma is defined by a positive response to the
following question:
Have you [has your child] had wheezing or
whistling in the chest in the past 12 months?
The environmental questionnaire for the 6-7-
year-old age group contained more questions on
early life exposures as this was completed by the
parents of the child. We restricted our analyses to
the risk factors which had shown associations witheither rhinoconjunctivitis, asthma, or eczema
symptoms in the last 12 months in previous ana-
lyses at the individual level. Variables included for
the younger age group (6–7 years) were paracet-
amol use in the first year of life and in the past 12
months,6 antibiotic use in the first year of life,7
breast feeding,8 pets in the home in the first year
of life,9 regular contact with farm animals in the
first year of life, and prenatally through maternal
contact,10 truck traffic in the last 12 months,11
fast food consumption in the last 12 months,12
television viewing in the last 12 months,13
parental smoking in the last 12 months,14 open
fire cooking,15 birth weight,16 and number of
siblings.17 For the older age group (13–14 years),
truck traffic,11 fast food consumption,12 television
viewing,13 parental smoking,14 and paracetamol
use,18 all in the past 12 months, open fire
cooking15 and number of siblings17 were
included.
Most of the above risk factors were para-
meterised as binary variables from “yes/no” ques-
tions in the environmental questionnaire. The
exceptions were: paracetamol use in the past 12
months (at least once per month vs. less than once
per month), heavy truck traffic (frequently or almost
the whole day vs. seldom or never), fast food
consumption (once per week or more vs. less than
once per week), television viewing (at least 1 h per
day vs. less than 1 h per day), birth weight (less
than 2.5 kg vs. at least 2.5 kg), and number of
siblings (2 or more siblings vs. 1 or no siblings).
Full definitions are in Table S1, Supporting
Material. The highest level of maternal education
was recorded as primary, secondary, tertiary or
missing/not stated.
Gross National Income (GNI) in 2002 was ob-
tained from the World Bank website22 where
available, with gaps filled by the CIA World
Factbook.23 Countries were classified as ‘affluent’
or ‘non-affluent’ using a 2001 GNI value of
US$9205 per capita as a cut-off, which separates
high-income countries from low and middle-
income countries.24Statistical analyses
Separate analyses were conducted for the 2 age
groups. Centres with fewer than 1000 individuals
in an age group were excluded from the analyses
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have at least 10 individuals to be included in the
analyses for that age group. In addition, a
response rate of at least 60% was required for
children and at least 70% for adolescents for a
centre to be included.
Mixed effect (multilevel) logistic regression
models were used for all analyses with random
intercepts at the 3 highest levels of the four-level
hierarchy: individuals, schools, centres and coun-
tries (from lowest to highest). All analyses addi-
tionally adjusted for sex and maternal education as
confounders at the individual level.
The potential risk factors for rhinoconjunctivitis
symptoms were compared at individual level and
at school level in a similar way to previous publi-
cations on asthma20 and eczema.21 The school-
level risk factors are less prone to reverse causa-
tion bias than the individual-level risk factors as a
change in behaviour of a few people with the
disease will not greatly affect the school-level
prevalence of that risk factor. Thus, similar results
at both levels can be interpreted as suggestive
evidence against reverse causation influencing
individual-level associations.
For comparison of risk factor associations be-
tween the 3 different diseases, 3 different model-
ling approaches were used:
i) Standard outcomes - modelling the 3 disease
outcomes separately but within the same sam-
ple of children,
ii) Multimorbid outcomes - modelling each of the
different combination of disease outcomes (i.e.
asthma only, eczema only, rhinoconjunctivitis
only, asthma and eczema, asthma and rhino-
conjunctivitis, eczema and rhinoconjunctivitis,
and all 3) against those with no disease and
comparing the resulting risk factor associations,
and
iii) Unimorbid outcomes - comparing individuals
with only asthma, only eczema or only rhino-
conjunctivitis symptoms in the last 12 months
and modelling the 3 combinations of disease
pairs to evaluate if the risk factors are more
associated with one disease than another.
In each of these modelling analyses we checked
for collinearity between the risk factors bycomparing the standard errors in the fully adjusted
model (all risk factors and confounders) to those in
minimally adjusted models (only the risk factor of
interest and the confounders).
Additionally, we ran each model separately for
"affluent" and "non-affluent" countries (with the
exception of the multimorbid outcomes analyses
where some of the sample sizes were too small).
We also tested for an interaction between country
affluence and each risk factor individually. Ana-
lyses were conducted using Stata version 15.25RESULTS
Derivation and characteristics of the sample
analysed
In the age 6–7 analyses there were 75 centres
(comprising 221,280 children) that met the stan-
dard ISAAC inclusion criteria1 of a minimum of
1000 children and a response rate of at least
60%. For multi-level analysis, 263 schools (1427
children in total) were excluded due to having
fewer than 10 children and a further 102,990
children excluded for not having data available for
all 3 outcomes (asthma, eczema, and rhino-
conjunctivitis symptoms), confounders (sex and
mother's level of education), and all the included
risk factors. The remaining 116,863 children, on
which these results are based (the “synthesis
sample”), were from 2163 schools within 59 cen-
tres, in 22 different countries (Fig. S1, Supporting
Material).
The prevalence of rhinoconjunctivitis symptoms
among the 6-7-year-olds included in this analysis
was 8.9%, asthma symptoms was 9.7%, and
eczema symptoms was 7.3%. The overall preva-
lence of the exposures ranged from 1.8% for cur-
rent open fire cooking to 80.5% for ever breastfed.
These and further summary statistics for the syn-
thesis sample are presented in Table 1.
For the 13-14 year-olds there were 122 centres
(comprising 362,048 adolescents) meeting the
ISAAC criteria1 of a minimum of 1000 per centre
and a response rate of at least 70%. For multi-
level analysis, 64 schools (comprising 298 in-
dividuals) were excluded due to having fewer than
10 adolescents. A further 137,314 individuals were
excluded for not having data available for all three
outcomes (asthma, eczema and rhinoconjunctivitis
Age 6–7 years (n ¼ 116,863) Age 13–14 years (n ¼ 224,436)
Individual-level
prevalence
Centre-level prevalence (%)
quartiles
Individual-level
Prevalence
Centre-level prevalence (%)
quartiles
Type Variable (%) Min Q1 Med Q3 Max (%) Min Q1 Med Q3 Max
Outcome Rhinoconjunctivitis
in the past 12 months
8.9 0.9 3.7 7.5 12.2 25.2 14.1 1.2 8.8 13.2 18.5 31.7
Asthma symptoms
in the past 12 months
9.7 2.5 5.4 9.0 13.2 29.7 10.6 0.7 6.1 9.8 14.4 32.4
Eczema symptoms in
the past 12 months
7.3 0.6 2.5 6.0 10.9 18.9 6.2 0.1 3.0 4.7 8.0 23.8
Multiple
outcome No symptoms 80.1 62.2 74.1 80.1 89.0 95.0 76.0 51.8 69.6 75.8 83.5 98.2
Rhinoconjunctivitis only 4.7 0.3 2.2 3.6 5.2 16.5 8.8 1.1 5.0 8.4 11.1 22.4
Asthma only 5.8 1.7 3.6 5.0 7.4 26.1 6.1 0.6 3.7 5.5 8.0 19.6
Eczema only 4.4 0.6 1.8 3.2 5.5 11.4 3.2 0.0 1.6 2.5 4.1 13.4
Rhinoconjunctivitis
and Asthma
2.1 0.2 0.8 2.0 3.3 4.9 2.9 0.0 1.4 2.6 4.0 10.3
Rhinoconjunctivitis
and Eczema
1.1 0.0 0.3 0.8 1.6 4.3 1.4 0.0 0.5 0.9 1.6 8.0
Asthma and Eczema 0.9 0.0 0.3 0.6 1.3 3.9 0.7 0.0 0.2 0.5 1.0 2.9
Symptoms of all three 0.9 0.0 0.2 0.8 1.4 3.3 0.9 0.0 0.3 0.8 1.2 4.1
Early life
exposure Low birthweight 7.7 0.0 5.2 6.2 9.4 39.4 NA NA NA NA NA NA
Breastfed ever 80.5 29.2 79.3 84.7 91.2 97.0 NA NA NA NA NA NA
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Age 6–7 years (n ¼ 116,863) Age 13–14 years (n ¼ 224,436)
Individual-level
prevalence
Centre-level prevalence (%)
quartiles
Individual-level
Prevalence
Centre-level prevalence (%)
quartiles
Type Variable (%) Min Q1 Med Q3 Max (%) Min Q1 Med Q3 Max
Farm animals (prenatal) 7.7 0.7 4.5 7.5 10.7 24.2 NA NA NA NA NA NA
Farm animals (1st year) 9.3 1.9 6.2 9.3 13.5 24.9 NA NA NA NA NA NA
Cat (1st year) 10.9 1.2 4.9 8.3 11.9 53.8 NA NA NA NA NA NA
Dog (1st year) 19.8 0.7 10.6 18.2 27.6 46.3 NA NA NA NA NA NA
Paracetamol (1st year) 66.1 8.6 59.0 68.1 82.7 93.9 NA NA NA NA NA NA
Antibiotics (1st year) 55.6 18.8 52.0 57.8 62.3 77.7 NA NA NA NA NA NA
Current
exposure 2 or more siblings 34.7 12.4 21.9 31.8 45.3 83.1 53.9 3.9 37.9 57.6 73.3 100.0
Heavy truck traffic (past
12 months)
37.9 6.3 32.1 37.8 43.8 67.4 39.5 15.2 32.3 38.0 45.0 90.9
Fast food (past 12
months)
39.6 9.3 20.4 42.4 54.3 98.1 53.6 6.1 42.7 53.7 66.4 98.3
Television (past 12
months)
80.1 40.1 72.9 82.2 89.1 95.3 85.7 42.9 80.9 90.0 93.2 98.0
Paternal tobacco (past
12 months)
31.7 3.2 19.9 28.9 43.6 55.3 38.5 2.7 23.9 36.4 46.4 94.1
Maternal tobacco
(past 12 months)
16.3 0.0 1.6 12.6 24.5 46.6 18.3 0.4 2.7 14.1 28.9 93.7
Paracetamol
(past 12 months)
17.8 0.0 9.9 15.7 23.9 65.3 26.7 0.0 18.4 28.6 34.7 66.0
Open fire cooking 1.8 0.0 0.3 1.1 2.0 44.8 5.2 0.0 0.6 1.3 4.1 86.1
Table 1. (Continued) Summary statistics for variables and their prevalence in subjects who had data present for the 3 outcomes, the confounders sex and maternal education level and all
other exposures of interest in the table (the “synthesis sample”)
6
Rutter
et
al.
W
orld
A
llerg
y
O
rg
anization
Journal(2020)13:100123
http
://d
oi.org
/10.1016/j.w
aojou.2020.100123
Volume 13, No. 6, Month 2020 7symptoms), confounders (sex and mother's level of
education) and all the included risk factors of in-
terest. The remaining “synthesis sample” contained
224,436 adolescents from 2037 schools within 97
centres, in 41 different countries (Fig. S2,
Supporting Material).
The prevalence of rhinoconjunctivitis symptoms
among the 13-14-year-olds included in this anal-
ysis was 14.1%, asthma symptoms was 10.6%, and
eczema symptoms was 6.2%. The overall preva-
lence of the exposures ranged from 5.2% for cur-
rent open fire cooking to 85.7% for watching
television at least an hour a day. For further details,
see Table 1.
Multi-level models for rhinoconjunctivitis
Table 2 presents associations at the individual
level (within schools) and the area level (between
schools, within centre) for exposures of interest,
adjusted for sex and mother's educational level
(“minimally adjusted”), and for each other (“fully
adjusted”), as derived from the multi-level model.
For the 6–7 age group, the strongest mutually
adjusted associations with rhinoconjunctivitis at
the individual level were current paracetamol use
(odds ratio ¼ 2.02; 95% CI ¼ 1.92–2.13) and anti-
biotics in the first year (1.58; 1.51–1.66). These as-
sociations were very similar at the school level with
odds ratios 2.04 (1.43–2.89) and 1.39 (1.03–1.88)
respectively. However, the weaker child-level as-
sociation with early paracetamol use (1.39; 1.32–
1.47) was not seen at the school level (0.99; 0.73–
1.35). Similarly, a modest child-level association
with heavy truck traffic (1.17; 1.12–1.22) was
inconsistent with the inverse relationship at school
level (odds ratio 0.92; 0.73–1.16). Low birthweight
showed no evidence of an association with rhino-
conjunctivitis at the individual level (1.04; 0.96–
1.13), but at the school level the association was
strong and significant (2.59; 1.56–4.29). Similarly, a
school-level association was evident for television
viewing (1.45; 1.05–2.01) but not for children
within schools (0.93; 0.88–0.98).
In the 13–14 age group, there was a strong as-
sociation at the individual level with current para-
cetamol use (1.76; 1.71–1.81) which was even
stronger at the school-level (3.48; 2.66–4.56). A
less strong child-level association was observed for
heavy truck traffic (1.23; 1.20–1.26), which wasconsistent at the school level (1.16; 0.94–1.44)
though there was less precision on the latter esti-
mate. Paternal and maternal smoking had similar
effects at the individual-level, but at the school
level their associations were in opposite directions.
For cooking by open fire, the school-level associ-
ation (2.02; 1.39–2.93) was much stronger than the
child-level association (1.16; 1.08–1.26).
The precision of estimates from the fully
adjusted models and those from the correspond-
ing minimally adjusted models (Table 2) were
compared and no evidence of collinearity was
found.Comparison of risk factor patterns for
rhinoconjunctivitis, asthma and eczema
Table 3 compares, by age group, the individual-
level associations of each exposure with symptoms
of rhinoconjunctivitis (from Table 2), asthma, and
eczema (previously published in slightly different
samples20,21 but reanalysed here on the same
“synthesis sample” as for rhinoconjunctivitis).
For younger children, the strongest associations
in the fully adjusted analyses were similar across all
3 outcomes. They were: current paracetamol use
(ORs for rhinoconjunctivitis symptoms 2.02;
asthma symptoms 2.07; and eczema symptoms
1.46), antibiotic use in the first year of life (1.58;
1.66; 1.40, respectively), and paracetamol use in
the first year of life (1.39; 1.34; 1.29). Heavy truck
traffic showed a less strong but consistent associ-
ation with all 3 outcomes (1.17; 1.19; 1.12). Simi-
larly, cat ownership in the first year of life had a
consistent direction of association, somewhat
stronger with asthma (1.22) than with rhino-
conjunctivitis (1.09) and eczema (1.10).
The 3 diseases differed in their associations with
some other risk factors. Exposures showing a
harmful association with asthma but no statistically
significant association with rhinoconjunctivitis and
eczema were cooking on an open fire and fast
food. Low birthweight showed a harmful associa-
tion with asthma (OR ¼ 1.15), a marginally statis-
tically significant protective effect with eczema
(OR ¼ 0.90), and no association with rhino-
conjunctivitis. Breast feeding was associated with
increased risk of eczema (1.11), a marginally sta-
tistically significant protective association with
Age group Exposures ofinterest
Minimally adjusted modelb Fully adjusted modelc
Individual-level School-level Individual-level School-level
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
6–7 years
(n ¼ 116,863)
Low
birthweight
1.11
(1.02, 1.20)
3.03
(1.88, 4.88)
1.04
(0.96, 1.13)
2.59
(1.56, 4.29)
Breastfed ever 0.97
(0.92, 1.02)
0.52
(0.37, 0.73)
1.00
(0.95, 1.06)
0.62
(0.44, 0.88)
Farm animals
(prenatal)
1.36
(1.27, 1.46)
1.56
(1.10, 2.22)
1.18
(1.07, 1.30)
1.16
(0.61, 2.20)
Farm animals
(1st year)
1.30
(1.21, 1.39)
1.55
(1.11, 2.16)
1.07
(0.98, 1.17)
1.19
(0.65, 2.18)
Cat (1st year) 1.19
(1.11, 1.27)
1.36
(0.94, 1.97)
1.09
(1.01, 1.16)
1.10
(0.72, 1.68)
Dog (1st year) 1.16
(1.10, 1.21)
1.21
(0.89, 1.63)
1.07
(1.01, 1.12)
0.94
(0.67, 1.31)
Paracetamol
(1st year)
1.80
(1.71, 1.89)
1.32
(1.01, 1.75)
1.39
(1.32, 1.47)
0.99
(0.73, 1.35)
Antibiotics (1st
year)
1.84
(1.75, 1.92)
1.45
(1.09, 1.91)
1.58
(1.51, 1.66)
1.39
(1.03, 1.88)
2 or more
siblings
0.99
(0.95, 1.04)
1.04
(0.83, 1.30)
0.98
(0.94, 1.03)
0.88
(0.69, 1.12)
Heavy truck
traffic (current)
1.25
(1.20, 1.31)
1.12
(0.90, 1.40)
1.17
(1.12, 1.22)
0.92
(0.73, 1.16)
Fast food
(current)
1.04
(0.99, 1.09)
1.13
(0.89, 1.42)
0.99
(0.94, 1.03)
1.04
(0.82, 1.32)
Television
(current)
0.98
(0.92, 1.03)
1.59
(1.18, 2.14)
0.93
(0.88, 0.98)
1.45
(1.05, 2.01)
Paternal
tobacco
(current)
1.11
(1.06, 1.16)
1.34
(1.03, 1.74)
1.07
(1.02, 1.12)
0.86
(0.63, 1.19)
Maternal
tobacco
(current)
1.12
(1.06, 1.19)
1.67
(1.25, 2.23)
1.05
(0.99, 1.11)
1.39
(0.98, 1.96)
Paracetamol
(current)
2.30
(2.18, 2.42)
2.30
(1.66, 3.20)
2.02
(1.92, 2.13)
2.04
(1.43, 2.89)
Open fire
cooking
(current)
1.03
(0.86, 1.23)
2.21
(1.16, 4.22)
0.99
(0.82, 1.19)
1.85
(0.92, 3.71)
(continued)
8 Rutter et al. World Allergy Organization Journal (2020) 13:100123
http://doi.org/10.1016/j.waojou.2020.100123
Age group Exposures ofinterest
Minimally adjusted modelb Fully adjusted modelc
Individual-level School-level Individual-level School-level
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
13–14 years
(n ¼ 224,436)
2 or more
siblings
1.05
(1.02, 1.08)
1.02
(0.83, 1.25)
1.04
(1.01, 1.07)
0.93
(0.75, 1.15)
Heavy truck
traffic (current)
1.27
(1.24, 1.30)
1.35
(1.09, 1.67)
1.23
(1.20, 1.26)
1.16
(0.94, 1.44)
Fast food
(current)
1.10
(1.07, 1.13)
1.31
(1.07, 1.61)
1.06
(1.03, 1.08)
1.24
(1.02, 1.51)
Television
(current)
1.04
(1.00, 1.08)
1.35
(0.97, 1.88)
1.01
(0.97, 1.05)
1.20
(0.86, 1.68)
Paternal
tobacco
(current)
1.16
(1.13, 1.19)
1.08
(0.84, 1.40)
1.10
(1.07, 1.13)
0.75
(0.55, 1.00)
Maternal
tobacco
(current)
1.21
(1.17, 1.25)
1.46
(1.08, 1.97)
1.14
(1.10, 1.17)
1.56
(1.12, 2.18)
Paracetamol
(current)
1.80
(1.75, 1.85)
3.52
(2.69, 4.60)
1.76
(1.71, 1.81)
3.48
(2.66, 4.56)
Open fire
cooking
(current)
1.16
(1.08, 1.25)
1.73
(1.19, 2.49)
1.16
(1.08, 1.26)
2.02
(1.39, 2.93)
Table 2. (Continued) Individual-level (within school) and school-level (between school) effects of exposures on rhinoconjunctivitis
symptoms using the synthesis samplea. Mixed logistic regression models with random intercepts at the school, centre and country levels.
a. Synthesis sample contains individuals with data present for all 3 outcomes, sex, maternal education and all exposures of interest. b. Adjusted for sex and
mothers level of education. c. Adjusted for sex, mothers level of education and all other variables in the table (within age group)
Volume 13, No. 6, Month 2020 9asthma (OR ¼ 0.95) and no association with
rhinoconjunctivitis.
Among adolescents, exposures showing
consistent associations with all 3 diseases were
current paracetamol use (odds ratios for rhino-
conjunctivitis 1.76; asthma 1.80; and eczema 1.58),
heavy truck traffic (1.23; 1.20; 1.31, respectively),
cooking on an open fire (1.16; 1.19; 1.49), mother
smoking (1.14; 1.22; 1.11), and father smoking
(1.10; 1.11; 1.15). Weaker associations with fast
food were also consistent (1.06; 1.07; 1.06) across
the 3 diseases (Table 3).Comparison of risk factor patterns in affluent and
less affluent countries
Fig. 1A–C summarise the risk factor-disease as-
sociations by age group, stratified by national per
capita GNI (Numerical results are shown inTable S2, Supporting Material.). Many of the risk
factor-disease associations are fairly consistent
between affluent and non-affluent settings, with
most differences being within the range expected
by chance (interaction p > 0.01). In the section
below we focus upon the most significant in-
consistencies (interaction p < 0.0001 for one or
more diseases).
For rhinoconjunctivitis among 6-7-year-olds
(Fig. 1A and B), notable differences by national per
capita GNI are increased risk in non-affluent
countries with farm animal contact in infancy
(1.19; 1.07–1.33) and having more than two sib-
lings (1.06; 1.00–1.13), whereas in affluent coun-
tries, these associations are protective (0.88; 0.75–
1.03 and 0.87; 0.81–0.94, respectively).
For asthma among 6-7-year-olds (Fig. 1A and B),
farm animal exposure in pregnancy showed a
Age group Exposures of interest
Fully adjusted modela
Rhinoconjunctivitis
symptoms
Asthma
symptoms
Eczema
symptoms
OR (95% CI) OR (95% CI) OR (95% CI)
6–7 years (n ¼
116,863)
Low birthweight 1.04
(0.96, 1.13)
1.15
(1.07, 1.25)
0.90
(0.82, 0.99)
Breastfed ever 1.00
(0.95, 1.06)
0.95
(0.90, 1.00)
1.11
(1.04, 1.17)
Farm animals
(prenatal)
1.18
(1.07, 1.30)
1.19
(1.08, 1.30)
1.12
(1.01, 1.24)
Farm animals (1st
year)
1.07
(0.98, 1.17)
0.98
(0.89, 1.06)
1.13
(1.03, 1.25)
Cat (1st year) 1.09
(1.01, 1.16)
1.22
(1.14, 1.30)
1.10
(1.02, 1.18)
Dog (1st year) 1.07
(1.01, 1.12)
1.03
(0.98, 1.08)
1.06
(1.00, 1.12)
Paracetamol (1st
year)
1.39
(1.32, 1.47)
1.34
(1.27, 1.41)
1.29
(1.22, 1.37)
Antibiotics (1st year) 1.58
(1.51, 1.66)
1.66
(1.59, 1.74)
1.40
(1.33, 1.47)
2 or more siblings 0.98
(0.94, 1.03)
0.97
(0.92, 1.01)
0.94
(0.90, 0.99)
Heavy truck traffic
(current)
1.17
(1.12, 1.22)
1.19
(1.14, 1.24)
1.12
(1.06, 1.17)
Fast food (current) 0.99
(0.94, 1.03)
1.08
(1.04, 1.13)
0.99
(0.94, 1.05)
Television (current) 0.93
(0.88, 0.98)
1.05
(0.99, 1.11)
0.96
(0.90, 1.02)
Paternal tobacco
(current)
1.07
(1.02, 1.12)
1.10
(1.05, 1.16)
1.04
(0.99, 1.10)
Maternal tobacco
(current)
1.05
(0.99, 1.11)
1.20
(1.14, 1.27)
1.05
(0.99, 1.12)
Paracetamol (current) 2.02
(1.92, 2.13)
2.07
(1.97, 2.17)
1.46
(1.38, 1.55)
Open fire cooking
(current)
0.99
(0.82, 1.19)
1.21
(1.04, 1.42)
1.14
(0.96, 1.35)
(continued)
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Age group Exposures of interest
Fully adjusted modela
Rhinoconjunctivitis
symptoms
Asthma
symptoms
Eczema
symptoms
OR (95% CI) OR (95% CI) OR (95% CI)
13–14 years (n ¼
224,436)
2 or more siblings 1.04
(1.01, 1.07)
1.02
(0.99, 1.06)
1.08
(1.04, 1.12)
Heavy truck traffic
(current)
1.23
(1.20, 1.26)
1.20
(1.16, 1.23)
1.31
(1.26, 1.36)
Fast food (current) 1.06
(1.03, 1.08)
1.07
(1.04, 1.10)
1.06
(1.02, 1.10)
Television (current) 1.01
(0.97, 1.05)
1.02
(0.97, 1.07)
1.07
(1.01, 1.14)
Paternal tobacco
(current)
1.10
(1.07, 1.13)
1.11
(1.07, 1.14)
1.15
(1.11, 1.20)
Maternal tobacco
(current)
1.14
(1.10, 1.17)
1.22
(1.18, 1.27)
1.11
(1.06, 1.17)
Paracetamol (current) 1.76
(1.71, 1.81)
1.80
(1.75, 1.86)
1.58
(1.52, 1.65)
Open fire cooking
(current)
1.16
(1.08, 1.26)
1.19
(1.10, 1.30)
1.49
(1.34, 1.65)
Table 3. (Continued) Single outcome models of fully adjusteda, individual-level (within school) effects of exposures using the synthesis
sampleb. Mixed logistic regression models with random intercepts at the school, centre and country levels. a. Adjusted for sex, mothers level of
education and for all other variables in the table (within age group). b. Synthesis sample contains individuals with data present for all 3 outcomes, sex, maternal
education and all exposures of interest
Volume 13, No. 6, Month 2020 11harmful association in non-affluent countries (1.32;
1.18–1.49) but no significant effect in affluent
countries (0.98; 0.83–1.14). Breastfeeding ever
showed a protective effect in non-affluent coun-
tries (0.87; 0.81–0.94) but no significant effect in
affluent countries (1.02; 0.96–1.10). Cat exposure
in infancy increased risk of asthma symptoms in
both settings, but there was evidence of a stronger
effect in non-affluent (1.36; 1.24–1.49) than affluent
countries (1.10; 1.01–1.20). Conversely, current
paracetamol use elevated asthma risk to a signifi-
cantly greater extent in affluent (2.36; 2.19–2.56)
than non-affluent settings (1.90; 1.78–2.02).
For eczema among 6-7-year-olds (Fig. 1A and
B), early cat exposure was a risk factor in non-
affluent countries (1.23; 1.11–1.36) but not in
affluent countries (0.99; 0.90–1.09). Farm animal
exposure in infancy increased eczema risk in non-
affluent (1.25; 1.11–1.40) but not in affluent coun-
tries (0.95; 0.80–1.13), and a similar pattern was
evident for farm animal exposure in pregnancy.
Current paracetamol use was more stronglyassociated with eczema symptoms in affluent
(1.65; 1.50–1.81) than non-affluent settings (1.35;
1.25–1.46), although this heterogeneity (interaction
p ¼ 0.003) was less significant than for asthma.
Stratifying the 13-14 year-old results in a similar
manner (Fig. 1C and Table S2), few risk factors
demonstrate differential effects in affluent and
non-affluent countries. For rhinoconjunctivitis,
open fire cooking increased risk in non-affluent
countries (1.20; 1.11–1.30) but not in affluent
countries (0.82; 0.62–1.07) (interaction p ¼ 0.008).
Across all 3 outcomes, current paracetamol use
showed a harmful effect in both affluent and non-
affluent countries, but the effect was stronger in
affluent countries (interaction p < 0.0001 for rhi-
noconjunctivitis, p ¼ 0.0009 for asthma, p ¼ 0.009
for eczema).Multimorbid (combinations of disease) models
In the 6-7 year-old synthesis sample, 80.1% of
the children had no symptoms of any of the 3
outcomes. The proportion of children with only 1
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Volume 13, No. 6, Month 2020 13disease was 14.9% (rhinoconjunctivitis 4.7%,
asthma 5.8%, eczema 4.4%). The proportions with
2 diseases was 4.1% (rhinoconjunctivitis and
asthma 2.1%, rhinoconjunctivitis and eczema 1.1%,
and asthma, and eczema 0.9%). Just 0.9% of the
sample had symptoms of all 3 diseases (Table 1).
Using models comparing different combina-
tions of disease outcomes to those with no disease
(Table 4), we found that antibiotics in the first year
of life showed a stronger effect among individuals
with 2 or 3 diseases. Paracetamol in the first year
had similar effects across any combination of the
diseases, with a slightly stronger effect only
noticed with individuals who have all 3 diseases.
This was similar for current heavy truck traffic.
Current paracetamol showed a stronger effect in
asthma and rhinoconjunctivitis than eczema, as
reflected in the combinations of multiple diseases
with the strongest effects being in individuals
with all 3 diseases or rhinoconjunctivitis and
asthma (Table 4).
Among the 13-14 year-old synthesis sample,
76.0% had no symptoms of any of the 3 outcomes.
The proportion of adolescents with only 1 disease
was 18.1% (rhinoconjunctivitis 8.8%, asthma 6.1%,
eczema 3.2%). A further 5.0% had symptoms of 2
of the diseases (rhinoconjunctivitis and asthma
2.9%, rhinoconjunctivitis and eczema 1.4% and
asthma and eczema 0.7%). Only 0.9% had symp-
toms of all 3 diseases (Table 1).
Current paracetamol showed a stronger effect
in individuals with more than one disease, with the
strongest effect in those with all 3 diseases. Open
fire cooking showed a stronger effect in all com-
binations that contain eczema (Table 4).
Importantly, in both age groups, risk factor as-
sociations with each disease in the whole popula-
tion (Table 3) persisted among children with only 1
condition, after exclusion of multimorbid groups
(Table 4).Fig. 1 Mutually adjusted odds ratios and 95% confidence intervals for
three diseases, in affluent countries and non-affluent countries. 1A 6-7-
13-14-year-olds, current exposures. Results from mixed logistic regressi
levels. Adjusted for sex, mother's level of education and all other variabl
shown in Table 3, stratified by country-level affluence. Results for affluen
aged 13–14). Results for non-affluent countries shown as circles (N ¼ 7
conjunctivitis symptoms (R) shown in yellow. Results for asthma symptom
Data points are tabulated in Supplementary Table S2.Unimorbid (single disease case-only) models
Table 5 shows the results of 3 separate models,
each comparing 2 of the unimorbid outcomes.
Corresponding results, stratified by per capita
GNI, are shown as Table S3 in the Supporting
Material. Triangle plots appear as Figs. S3–S8 in
the Supporting Material. An equilateral central
triangle denotes a risk factor that has a similar
strength of effect on all 3 diseases, the further
from equilateral the triangle is, the more that risk
factor effect differs in strength between diseases.
In the plots the odds ratios displayed are all
greater than or equal to one; they relate to
whichever disease has the stronger effect (the
corner they are closest to compared to the
opposite corner).
In the 6-7 year-old age group, low birthweight
was most strongly associated with asthma and
more strongly associated with rhinoconjunctivitis
than eczema. Early life antibiotic exposure showed
a similar pattern but to a slightly reduced extent.
Being breastfed ever showed a stronger associa-
tion with eczema than both asthma and rhino-
conjunctivitis. Owning a cat in the first year of life
was most strongly associated with asthma but
more strongly associated with eczema than
rhinoconjunctivitis.
Some differences were evident between affluent
and non-affluent countries (Table S3 and Fig. S6).
Farm animal contact during pregnancy had
effects in non-affluent countries which were more
balanced between the diseases, but in affluent
countries the effect was stronger on eczema and
rhinoconjunctivitis than asthma. In contrast, early
cat contact had more balanced effects in affluent
countries, but in non-affluent countries there was a
much stronger effect on asthma and eczema than
rhinoconjunctivitis.
Among the current exposures for 6-7 year-olds,
current paracetamol use was more strongly asso-
ciated with asthma and rhinoconjunctivitis thanindividual-level associations between risk factors and each of the
year-olds, early exposures. 1B 6-7-year-olds, current exposures. 1C
on models with random intercepts at the school, centre and country
es shown for the same age group. Based on the synthesis sample as
t countries shown as diamonds (N ¼ 41,831 aged 6–7; N ¼ 46,932
5,032 aged 6–7; N ¼ 177,504 aged 13–14). Results for rhino-
s (A) shown in blue. Results for eczema symptoms (E) shown in red.
RC
only
Asthma
only
Eczema
only
RC
and Asthma
RC
and Eczema
Asthma
and
Eczema
RC,
Asthma and Eczema
Exposures of
interest OR (95% CI)
OR
(95% CI)
OR
(95% CI) OR (95% CI) OR (95% CI)
OR
(95% CI) OR (95% CI)
Age 6–7
years
Reference group with no disease, n0 ¼ 93,554
n1 ¼ 5508 n1 ¼ 6720 n1 ¼ 5099 n1 ¼ 2503 n1 ¼ 1310 n1 ¼ 1074 n1 ¼ 1095
Low
birthweight
0.98
(0.88, 1.10)
1.16
(1.05, 1.27)
0.85
(0.75, 0.96)
1.14
(0.98, 1.33)
0.96
(0.76, 1.20)
0.90
(0.70, 1.16)
1.14
(0.91, 1.44)
Breastfed
ever
0.98
(0.91, 1.05)
0.93
(0.87, 1.00)
1.12
(1.03, 1.21)
0.96
(0.86, 1.06)
1.10
(0.95, 1.28)
0.98
(0.84, 1.15)
1.12
(0.96, 1.32)
Farm animals
(prenatal)
1.17
(1.03, 1.34)
1.14
(1.01, 1.28)
1.06
(0.93, 1.22)
1.22
(1.01, 1.47)
1.07
(0.84, 1.37)
1.19
(0.89, 1.58)
1.56
(1.20, 2.03)
Farm animals
(1st year)
1.11
(0.99, 1.25)
1.03
(0.92, 1.15)
1.17
(1.03, 1.32)
0.97
(0.82, 1.16)
1.40
(1.13, 1.74)
1.04
(0.80, 1.35)
0.86
(0.66, 1.12)
Cat
(1st year)
0.97
(0.88, 1.07)
1.21
(1.12, 1.31)
1.08
(0.99, 1.18)
1.29
(1.14, 1.47)
1.19
(1.00, 1.42)
1.06
(0.89, 1.27)
1.16
(0.97, 1.39)
Dog
(1st year)
1.07
(1.00, 1.15)
1.01
(0.94, 1.08)
1.07
(1.00, 1.15)
1.08
(0.98, 1.20)
1.05
(0.92, 1.20)
0.99
(0.86, 1.15)
1.14
(0.99, 1.32)
Paracetamol
(1st year)
1.38
(1.29, 1.48)
1.32
(1.24, 1.41)
1.26
(1.17, 1.35)
1.45
(1.30, 1.62)
1.49
(1.29, 1.72)
1.35
(1.14, 1.60)
1.82
(1.52, 2.18)
Antibiotics
(1st year)
1.44
(1.36, 1.54)
1.56
(1.47, 1.65)
1.25
(1.17, 1.33)
1.95
(1.77, 2.15)
1.82
(1.60, 2.07)
2.13
(1.84, 2.47)
2.37
(2.03, 2.76)
2 or more
siblings
0.98
(0.92, 1.04)
0.96
(0.90, 1.01)
0.94
(0.88, 1.00)
0.98
(0.90, 1.08)
0.91
(0.81, 1.03)
0.88
(0.77, 1.01)
0.99
(0.86, 1.13)
Heavy truck
traffic (current)
1.13
(1.06, 1.20)
1.18
(1.12, 1.24)
1.08
(1.01, 1.15)
1.19
(1.09, 1.29)
1.15
(1.02, 1.29)
1.11
(0.98, 1.26)
1.50
(1.32, 1.71)
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RC
only
Asthma
only
Eczema
only
RC
and Asthma
RC
and Eczema
Asthma
and
Eczema
RC,
Asthma and Eczema
Exposures of
interest OR (95% CI)
OR
(95% CI)
OR
(95% CI) OR (95% CI) OR (95% CI)
OR
(95% CI) OR (95% CI)
Age 6–7
years
Reference group with no disease, n0 ¼ 93,554
n1 ¼ 5508 n1 ¼ 6720 n1 ¼ 5099 n1 ¼ 2503 n1 ¼ 1310 n1 ¼ 1074 n1 ¼ 1095
Fast food
(current)
0.96
(0.90, 1.02)
1.08
(1.02, 1.15)
0.96
(0.90, 1.03)
1.06
(0.97, 1.16)
1.01
(0.89, 1.14)
1.21
(1.05, 1.38)
0.98
(0.86, 1.13)
Television
(current)
0.91
(0.85, 0.98)
1.07
(0.99, 1.15)
0.97
(0.90, 1.05)
1.02
(0.91, 1.14)
0.85
(0.73, 0.99)
1.05
(0.88, 1.25)
0.95
(0.80, 1.12)
Paternal
tobacco
(current)
1.05
(0.98, 1.12)
1.08
(1.02, 1.15)
1.02
(0.96, 1.10)
1.12
(1.03, 1.23)
0.93
(0.82, 1.06)
1.12
(0.97, 1.29)
1.22
(1.06, 1.40)
Maternal
tobacco
(current)
1.02
(0.94, 1.11)
1.24
(1.16, 1.33)
1.05
(0.97, 1.14)
1.21
(1.09, 1.36)
1.11
(0.94, 1.30)
1.30
(1.11, 1.53)
1.05
(0.89, 1.24)
Paracetamol
(current)
1.90
(1.77, 2.04)
1.96
(1.84, 2.08)
1.34
(1.24, 1.45)
2.86
(2.59, 3.15)
1.91
(1.66, 2.19)
2.17
(1.88, 2.51)
2.92
(2.53, 3.37)
Open fire
cooking
(current)
0.97
(0.75, 1.25)
1.28
(1.07, 1.55)
1.18
(0.96, 1.45)
1.17
(0.83, 1.67)
1.09
(0.70, 1.72)
1.21
(0.77, 1.91)
0.77
(0.43, 1.39)
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RC
only
Asthma
only
Eczema
only
RC
and Asthma
RC
and Eczema
Asthma
and
Eczema
RC,
Asthma and Eczema
Exposures of interest OR (95% CI) OR(95% CI)
OR
(95% CI) OR (95% CI) OR (95% CI)
OR
(95% CI) OR (95% CI)
Age 13–14 years Reference group with no disease, n0 ¼ 170,542
n1 ¼ 19,858 n1 ¼ 13,585 n1 ¼ 7104 n1 ¼ 6557 n1 ¼ 3219 n1 ¼ 1554 n1 ¼ 2017
2 or more siblings 1.02
(0.98, 1.06)
1.01
(0.97, 1.05)
1.06
(1.00, 1.12)
1.05
(0.99, 1.11)
1.18
(1.09, 1.29)
1.06
(0.95, 1.19)
1.12
(1.01, 1.24)
Heavy truck traffic (current) 1.19
(1.16, 1.23)
1.14
(1.09, 1.18)
1.26
(1.20, 1.33)
1.30
(1.23, 1.37)
1.44
(1.34, 1.55)
1.47
(1.33, 1.64)
1.56
(1.42, 1.71)
Fast food (current) 1.04
(1.01, 1.08)
1.06
(1.02, 1.10)
1.06
(1.00, 1.12)
1.13
(1.07, 1.19)
1.12
(1.04, 1.21)
1.13
(1.01, 1.26)
1.13
(1.02, 1.24)
Television (current) 1.03
(0.98, 1.08)
1.08
(1.02, 1.15)
1.09
(1.01, 1.19)
0.97
(0.89, 1.06)
1.23
(1.08, 1.41)
1.21
(1.01, 1.46)
0.80
(0.69, 0.92)
Paternal tobacco (current) 1.08
(1.04, 1.11)
1.10
(1.05, 1.14)
1.13
(1.07, 1.19)
1.14
(1.07, 1.20)
1.22
(1.13, 1.32)
1.16
(1.04, 1.30)
1.26
(1.14, 1.39)
Maternal tobacco (current) 1.09
(1.05, 1.14)
1.20
(1.15, 1.26)
1.07
(0.99, 1.14)
1.27
(1.19, 1.35)
1.19
(1.08, 1.31)
1.22
(1.06, 1.39)
1.32
(1.18, 1.49)
Paracetamol (current) 1.62
(1.56, 1.68)
1.69
(1.62, 1.76)
1.36
(1.29, 1.44)
2.34
(2.21, 2.47)
2.16
(2.00, 2.34)
2.12
(1.89, 2.36)
2.98
(2.71, 3.29)
Open fire cooking (current) 1.15
(1.05, 1.27)
1.12
(1.01, 1.25)
1.33
(1.15, 1.53)
1.09
(0.92, 1.28)
1.50
(1.22, 1.84)
1.93
(1.49, 2.50)
2.22
(1.76, 2.81)
Table 4. (Continued) Multi outcome models of fully adjusteda within school effects of exposures compared to a reference group with no disease. Mixed logistic regression models with random
intercepts at the school, centre and country levels. a. Adjusted for sex, mother's level of education and all other variables in the table for that age group
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Age group Exposures of Interest
Asthma v Eczema Asthma vRhinoconjunctivitis Rhinoconjunctivitis v Eczema
OR (95% CI) OR (95% CI) OR (95% CI)
6–7 years n ¼ 11,819 n ¼ 12,228 n ¼ 10,607
Low birthweight 1.40 (1.19, 1.64) 1.16 (0.99, 1.35) 1.11 (0.94, 1.32)
Breastfed ever 0.85 (0.76, 0.94) 0.94 (0.85, 1.05) 0.89 (0.80, 1.00)
Farm animals (prenatal) 1.03 (0.85, 1.23) 0.99 (0.82, 1.18) 1.04 (0.86, 1.26)
Farm animals (1st year) 0.90 (0.76, 1.06) 0.89 (0.75, 1.05) 0.98 (0.83, 1.17)
Cat (1st year) 1.12 (0.99, 1.26) 1.27 (1.11, 1.44) 0.83 (0.73, 0.96)
Dog (1st year) 0.94 (0.85, 1.04) 0.97 (0.87, 1.07) 0.95 (0.86, 1.05)
Paracetamol (1st year) 1.05 (0.95, 1.16) 0.96 (0.86, 1.06) 1.07 (0.96, 1.19)
Antibiotics (1st year) 1.26 (1.16, 1.38) 1.12 (1.03, 1.23) 1.14 (1.03, 1.25)
2 or more siblings 1.01 (0.93, 1.10) 0.99 (0.90, 1.08) 1.03 (0.94, 1.13)
Heavy truck traffic (current) 1.08 (1.00, 1.17) 1.05 (0.97, 1.14) 1.06 (0.97, 1.16)
Fast food (current) 1.12 (1.02, 1.22) 1.12 (1.03, 1.23) 1.00 (0.91, 1.10)
Television (current) 1.13 (1.01, 1.26) 1.16 (1.04, 1.29) 0.92 (0.82, 1.03)
Paternal tobacco (current) 1.03 (0.94, 1.12) 1.03 (0.94, 1.13) 1.02 (0.92, 1.12)
Maternal tobacco (current) 1.16 (1.04, 1.29) 1.21 (1.08, 1.35) 0.94 (0.84, 1.07)
Paracetamol (current) 1.45 (1.31, 1.60) 1.03 (0.93, 1.14) 1.48 (1.32, 1.65)
Open fire cooking (current) 1.02 (0.77, 1.35) 1.32 (0.95, 1.83) 0.72 (0.51, 1.01)
13–14 years n ¼ 20,689 n ¼ 33,443 n ¼ 26,962
2 or more siblings 0.94 (0.87, 1.01) 0.99 (0.94, 1.05) 0.96 (0.90, 1.03)
Heavy truck traffic (current) 0.92 (0.86, 0.99) 0.97 (0.92, 1.02) 0.93 (0.87, 0.98)
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http://doi.org/10.1016/j.waojou.2020.100123with eczema. Open fire cooking was more strongly
associated with both asthma and eczema than
rhinoconjunctivitis but the confidence intervals
were wide. Maternal smoking was more strongly
associated with asthma than with eczema or rhi-
noconjunctivitis. Affluent centres showed a stron-
ger effect of open fire cooking on asthma and
rhinoconjunctivitis, whereas in non-affluent centres
the stronger effect was on asthma and eczema.
Among 13-14 year-olds, similar to the younger
children, maternal smoking had a stronger asso-
ciation with asthma than with either eczema or
rhinoconjunctivitis, and current paracetamol
showed a stronger association with asthma and
rhinoconjunctivitis than with eczema. The biggest
difference between affluent and non-affluent
countries was observed for open fire cooking. In
affluent countries, there were stronger associations
with eczema than with asthma or rhinoconjuncti-
vitis, although it is important to note that the con-
fidence intervals were exceptionally large due to
the rarity of cooking on open fires in the affluent
centres.DISCUSSION
Overview of findings
This is the largest and broadest overview to date
of lifestyle and environmental risk factors for
symptoms of non-infective rhinoconjunctivitis
among children. It is the first comprehensive
analysis of this condition, which models multiple
risk factors together to compare their mutually
adjusted individual-level and population (school)-
level associations in a multilevel framework. Due to
the multiple comparisons made, and the large size
of our sample, we concentrate our interpretation
upon the overall patterns of results and on specific
findings with more extreme levels of statistical
significance.
Generally, associations with exposures aver-
aged at the school level were similar in direction
and magnitude to those ascertained at the child
level, as we found also for symptoms of asthma
and eczema. As we have argued elsewhere,20,21
this helps to exclude reverse causation,
particularly for exposures such as early
paracetamol and antibiotic use which may be
related to prodromal disease, or pets which may
Volume 13, No. 6, Month 2020 19be avoided by allergic families. An exception are
the results for breastfeeding, showing a
borderline significant inverse association with
asthma symptoms, a significantly positive
association with eczema symptoms, and a null
association with rhinoconjunctivitis at the
individual level (Table 3). Nevertheless, the
association of breastfeeding with
rhinoconjunctivitis at the school level is strongly
and significantly inverse (Table 2), perhaps
indicating confounding by socioeconomic or
other unmeasured characteristics of the school
catchment population. This contrasts with the
pattern of school-level associations of breast-
feeding with symptoms of asthma20 and
eczema,21 which were weakly positive but non-
significant.
Many of the risk factor associations observed for
symptoms of rhinoconjunctivitis were similar to
those previously reported for symptoms of asthma
or eczema in ISAAC Phase Three.6–21 Since the 3
diseases cluster together at the individual level, it
is possible that associations observed for one
disease could be influenced by risk factors for
other conditions in the triad. An innovative use of
ISAAC data in this paper is the analysis of
rhinoconjunctivitis, asthma and eczema, singly
and in combination.
As expected, we found that associations with
multimorbidity (combinations of 2 or 3 diseases)
were stronger than for each disease alone (unim-
orbidity). However, the relationships of risk factors
with each disease in the absence of the others
were of similar direction and magnitude to the
results for each condition modelled separately.
Thus, multimorbidity is not the sole explanation of
the common epidemiological patterns across
these three diseases.
For many risk factors, associations were consis-
tent across the 3 diseases, between the 2 age
groups, and between countries with different
levels of per capita Gross National Income. This
similarity of epidemiology strongly suggests that
there are common biological mechanisms for
these 3 diseases, which operate in both affluent
and less affluent settings. The most striking
example of this in our ISAAC dataset is current
paracetamol exposure, which was consistently
associated with each of the 3 diseases, withinschools and between schools, in both age groups
and in richer and poorer countries, although
somewhat more strongly with rhinoconjunctivitis
and asthma than with eczema.
Shared mechanisms do not exclude the possi-
bility of disease-specific pathways, which may
differ between higher and lower income countries.
An example of the latter is the inverse association
of seasonal rhinoconjunctivitis with number of
siblings and childhood exposure to the farm
environment. This is well established from large
epidemiological studies in Europe and confirmed
by objective markers of allergic sensitisation.26
This pattern is consistent with our findings for
rhinoconjunctivitis symptoms in affluent countries
but contrasts with the increased risk of these
symptoms among children from larger families
and those exposed to farm animals in poorer
countries.
Strengths and limitations
ISAAC Phase Three has substantial advantages
in terms of large sample sizes drawn from diverse
study centres worldwide, who adopted stand-
ardised methods of data collection. Reliance solely
upon questionnaires completed by parents (for the
6-7-year-olds) or participants (for the 13-14-year-
olds) is a limitation, both for definition of disease
outcomes and for ascertainment of risk factors. On
the other hand, the questionnaire methodology
maintained high response rates in each centre.
Misclassification of disease or risk factor infor-
mation could be non-systematic, leading to
weaker associations, or systematic, potentially
exaggerating, or masking associations. A particular
concern would be individual differences in the
threshold for reporting of symptoms, which could
exaggerate clustering of the 3 complaints within
individual children. This is unlikely to affect risk
factor associations in our unimorbid analysis,
where similarity in the epidemiological patterns for
the each of the 3 diseases (in the absence of the
others, Table 4) would be biased only if reporting
of all 3 diseases were altered by the presence of
the risk factor (or conversely, reporting of the
common risk factor were biased to a similar
degree by the presence of each of the 3 diseases).
A particular limitation of ISAAC Phase Three is
the lack of objective information on allergic
20 Rutter et al. World Allergy Organization Journal (2020) 13:100123
http://doi.org/10.1016/j.waojou.2020.100123sensitisation. This was measured by skin prick
testing and serum allergen-specific IgE in a sepa-
rate study of more than 50,000 10-11-year-old
children in 30 centres from 22 countries (ISAAC
Phase Two).3–5,27 Although (as expected)
symptoms of rhinoconjunctivitis, asthma and
eczema were more common among children with
positive skin prick tests, these associations were
substantially weaker in less affluent settings. The
proportion of each disease attributable to skin
prick positivity in centres from lower-income
countries (per capita GNI < USD 9200 in 2001)
was 14% for rhinoconjunctivitis, 20% for asthma
but only 1% for eczema. The corresponding pop-
ulation attributable fractions (PAFs) in higher-
income countries were 61% for rhinoconjunctivi-
tis, 46% for asthma, and 28% for eczema. The PAF
estimates were very similar when serum allergen-
specific IgE was used as the measure of allergic
sensitisation.4
Throughout, ISAAC has focused upon the
combination of nasal and conjunctival symptoms
(in the absence of intercurrent infection) as the
most relevant definition of rhinoconjunctivitis
because non-infective rhinitis alone (without itchy
eyes) is less strongly associated with skin prick
positivity (PAFs of 5% in less affluent centres and
10% in more affluent centres).27 More recent
studies, among adolescents28 and adults29 have
confirmed a stronger association of allergic
sensitisation with rhinoconjunctivitis than with
rhinitis alone.
A shared non-allergic mechanism for “atopic
diseases”?
In recent decades, two models of multi-
morbidity have been proposed to explain the
occurrence of 2 or more “atopic diseases” (asthma,
rhinitis, and eczema, sometimes extended also to
food allergy). The term “united airway disease” has
been proposed for the coexistence of asthma and
rhinitis in the same patient at the same time.30–32
The concept of the “atopic march” applies to the
sequential development of eczema, asthma, and
rhinitis (usually in that order) through childhood
and adolescence.33,34 Discussion of both
concepts has tended to focus upon IgE-mediated
allergic mechanisms and Th2-immune inflamma-
tory pathways as an explanation for concurrent and
longitudinal clustering of the 3 diseases.However, it is recognised that several distinct
pathways and mechanisms are likely to be
involved in the atopic march, some of them com-
mon and some disease-specific.34 Non-allergic
airway inflammation, defects of mucosal defence,
and exogenous cofactors (including microbes,
pollutants and smoking) have been proposed as
“treatable traits” underlying united airway dis-
ease,32 in addition to the close association of both
asthma and rhinitis with IgE sensitisation,
particularly to multiple allergens.35
Genome-wide association studies have shown a
mixture of common and disease-specific signals
for asthma, hay fever, and eczema36 illustrated by
triangle plots derived from unimorbid case-only
comparisons similar to those we have shown in
Table 5 and Figs. S3–S8. Filaggrin (FLG) variants
are specifically associated with eczema, whereas
other genome-wide significant loci such as IL6R
show almost perfect symmetry in association with
each of the 3 diseases. A bioinformatics (data-
mining) analysis of protein interactions found that
asthma, rhinitis, and eczema shared more associ-
ated proteins than would be expected by chance
and identified 15 pathways potentially involved in
the multimorbidity of asthma, rhinitis, and eczema,
although many of these are related to Th2-immune
signalling pathways.37
Epidemiological evidence for non-allergic
mechanisms underlying coexistence of asthma,
rhinitis, and eczema emerges from the collabora-
tive analysis of European birth cohorts by the
MeDALL consortium.38 Among over 8000 children
followed from birth to 4 and 8 years of age, IgE
sensitisation to common food and aero-allergens
at age 4 years accounted for only 38% of the co-
occurrence of 2 or more conditions (asthma,
rhinitis, and eczema) at age 8 years. In relative
terms, the strength of the association among the 3
diseases was higher in non-sensitised children,
although the excess comorbidity was greater
among those who were sensitised, due to a higher
baseline risk of disease. Among the sensitised
children, about a quarter of the observed comor-
bidity was not due to chance, whereas among non-
sensitised children the non-chance proportion was
more than half at age 8 years. Comorbidity at age
4 years was strongly predictive of comorbidity at
age 8 years. All these observations led the MeD-
ALL investigators to propose “a new vision of
Volume 13, No. 6, Month 2020 21multimorbidity independent of IgE sensitisation”,39
which would be entirely consistent with our
observations of common epidemiological
patterns for symptoms of rhinoconjunctivitis,
asthma, and eczema in 2 age groups of children
in both affluent and non-affluent countries
worldwide.
CONCLUSIONS
Most of the environmental and lifestyle corre-
lates of rhinoconjunctivitis, asthma, and eczema in
childhood display similarity across the 3 condi-
tions, even in less affluent settings where allergic
sensitisation (as conventionally defined) is less
likely to explain the concordant epidemiological
patterns. This supports the view that mechanisms
other than IgE-mediated tissue inflammation may
contribute a substantial proportion of the clus-
tering of these “atopic diseases” within individuals
(concurrently and sequentially) and at the popu-
lation level.
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